Curevac announces financial results for the third quarter and first nine months of 2024 and provides business update

Strengthened cash, strategic refocus and pipeline progress define transformative quarter €400 million upfront payment from restructured gsk collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 cvgbm phase 1 glioblastoma study showed 77% of patients with antigen-specific t-cell responses; data presented at esmo, sitc and sno new off-the-shelf program for squamous non-small cell lung cancer started, expected to enter phase 1 in h2 2025 new preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines positive phase 2 data from seasonal influenza program licensed to gsk demonstrated strong immune responses against challenging influenza b as well as a strains; program progressing to phase 3, which will be associated with significant milestone payment corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility appointment of seasoned industry executive axel malkomes as new cfo effective november 11, enhancing financial leadership and strategic execution curevac to host conference call and webcast today at 9 a.m. est / 3 p.m.
CVAC Ratings Summary
CVAC Quant Ranking